Anticancer activity of stoppin based on a novel peptide delivery system

Gao,Yan‑Fang; Wei,Xue‑Ni; Ye,Xiao‑Lei; Weng,Guo‑Bin; Chen,Yi‑Chen; Zhao,Ya‑Rong; Ji,Hui

doi:10.3892/mmr.2015.4024

October-2015 Volume 12 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2015 Volume 12 Issue 4

Full Size Image

Article

Anticancer activity of stoppin based on a novel peptide delivery system

Authors:
- Yan‑Fang Gao
- Xue‑Ni Wei
- Xiao‑Lei Ye
- Guo‑Bin Weng
- Yi‑Chen Chen
- Ya‑Rong Zhao
- Hui Ji
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Weifang People's Hospital, Weifang, Shandong 261040, P.R. China, School of Pharmacology, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Division of Drugs and Pharmacology, Ningbo Institute of Medical Sciences, Ningbo, Zhejiang 315000, P.R. China, Department of Urology, Yinzhou Second People's Hospital, Ningbo, Zhejiang 315100, P.R. China
Pages: 5437-5442
|
Published online on: July 2, 2015

https://doi.org/10.3892/mmr.2015.4024
Expand metrics +

Abstract

Stoppin (L1) is a newly identified anticancer peptide, which is a potent p53‑MDM2/MDMX inhibitor. Due to its limitation in cell delivery efficiency, a new peptide delivery system was developed based on a nucleic acid‑polypeptide‑liposome complex and its stability and effectiveness in vitro was investigated. The nucleic acid‑stoppin‑liposome complex was prepared and characterization of the complex was conducted. The stability of the complex was evaluated by enzyme digestion. Following transfection of the A549 cells with the complex, detection of green fluorescent protein (GFP) and luciferase activity was conducted to evaluate transfection efficiency. In addition, the anticancer activity of the complex was determined by 3‑(4,5‑dimethyl‑thiazolyl‑2)‑2,5 diphenyltetrazolium bromide assay and apoptosis was detected by flow cytometry. The results indicated that the particle size of the complex was 102±10 nm and the encapsulation rate was ~100% when the ratio of liposome, L1 and plasmid was: 4 µl:1 µg:2 µg. The enzyme digestion experiment demonstrated that the complex was resistant to pancreatic and DNA enzyme degradation, indicating that the complex had biological stability. Cell transfection demonstrated that it had a mutual promotion effect on delivery, which could be confirmed by GFP fluorescence and luciferase assay. The cell‑killing efficiency of this novel delivery system was three times higher than with stoppin alone at a low concentration. In conclusion, this novel stoppin peptide delivery system was stable. The nucleic acid‑peptide‑liposome complex can protect the internal component from the degradation of enzymes, promote entry of the peptide into the cells and enhance the anti‑tumor activity of stoppin. Therefore, it is a promising approach for peptide delivery, which can be characterized and visualized using plasmids with GFP or luciferase.

View Figures

View References

1	Shaji J and Patole V: Protein and Peptide drug delivery: Oral approaches. Indian J Pharm Sci. 70:269–277. 2008. View Article : Google Scholar : PubMed/NCBI
2	Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F and Neckers DC: A new approach to the oral administration of insulin and other peptide drugs. Science. 233:1081–1084. 1986. View Article : Google Scholar : PubMed/NCBI
3	Fix JA: Oral controlled release technology for peptides: Status and future prospects. Pharm Res. 13:1760–1764. 1996. View Article : Google Scholar : PubMed/NCBI
4	Mahato RI, Narang AS, Thoma L and Miller DD: Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst. 20:153–214. 2003. View Article : Google Scholar : PubMed/NCBI
5	Lindgren M, Hällbrink M, Prochiantz A and Langel U: Cell-penetrating peptides. Trends Pharmacol Sci. 21:99–103. 2000. View Article : Google Scholar : PubMed/NCBI
6	Fuchs SM and Raines RT: Pathway for polyarginine entry into mammalian cells. Biochemistry. 43:2438–2444. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lundin P, Johansson H, Guterstam P, Holm T, Hansen M, Langel U and EL Andaloussi S: Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem. 19:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
8	Li C, Liu M, Monbo J, Zou G, Li C, Yuan W, Zella D, Lu WY and Lu W: Turning a scorpion toxin into an antitumor miniprotein. J Am Chem Soc. 130:13546–13548. 2008. View Article : Google Scholar : PubMed/NCBI
9	Robinson JA: Design of protein-protein interaction inhibitors based on protein epitope mimetics. Chembiochem. 10:971–973. 2009. View Article : Google Scholar : PubMed/NCBI
10	Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
11	Li Y, Li B, Li CJ and Li LJ: Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors. Expert Opin Biol Ther. 15:437–454. 2015. View Article : Google Scholar
12	Geisert EE Jr, Del Mar NA, Owens JL and Holmberg EG: Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci Lett. 184:40–43. 1995. View Article : Google Scholar : PubMed/NCBI
13	Bangham AD and Horne RW: Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 8:660–668. 1964. View Article : Google Scholar : PubMed/NCBI
14	Accardo A, Aloj L, Aurilio M, Morelli G and Tesauro D: Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. Int J Nanomedicine. 9:1537–1557. 2014.PubMed/NCBI
15	Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N and Mixson AJ: Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect. 20:77–86. 2007. View Article : Google Scholar : PubMed/NCBI
16	Yang ZZ, Li JQ, Wang ZZ, Dong DW and Qi XR: Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 35:5226–5239. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sorgi FL, Bhattacharya S and Huang L: Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 4:961–968. 1997. View Article : Google Scholar
18	Immordino ML, Dosio F and Cattel L: Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1:297–315. 2006.
19	Yang W, Peters JI and Williams RO 3rd: Inhaled nanoparticles - a current review. Int J Pharm. 356:239–247. 2008. View Article : Google Scholar : PubMed/NCBI
20	Peer D, Park EJ, Morishita Y, Carman CV and Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 319:627–630. 2008. View Article : Google Scholar : PubMed/NCBI
21	Hutton DA, Pearson JP, Allen A and Foster SN: Mucolysis of the colonic mucus barrier by faecal proteinases: Inhibition by interacting polyacrylate. Clin Sci (Lond). 78:265–271. 1990. View Article : Google Scholar
22	Yamamoto A, Taniguchi T, Rikyuu K, et al: Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res. 11:1496–1500. 1994. View Article : Google Scholar : PubMed/NCBI
23	Langguth P, Bohner V, Biber J and Merkle HP: Metabolism and transport of the pentapeptide metkephamid by brush-border membrane vesicles of rat intestine. J Pharm Pharmacol. 46:34–40. 1994. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Anticancer activity of stoppin based on a novel peptide delivery system

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles